Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.
Source: MedWire News - Urology - Category: Urology & Nephrology Source Type: news
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology